WASHINGTON – Following a clean federal security review of the COVID-19 vaccine, the US will begin sharing its entire pipeline of vaccines from AstraZeneca, the White House told The Associated Press on Monday, as more than 60 million dots became available for export are supposed to. Months to come.
The move greatly expands on the action of the Biden administration last month to share about 4 million doses of the vaccine with Mexico and Canada. The AstraZeneca vaccine is widely in use worldwide but is not yet authorized by the US Food and Drug Administration.
The move comes as the White House is assured of a supply of three vaccines to be administered in the US, especially after a single-dose Johnson & Johnson restart on the weekend.
“Given the strong vaccine portfolio that the US already has and which has been authorized by the FDA, and given that the AstraZeneca vaccine is not authorized for use in the US, we have AstraZeneca here over the next several months There is no need to use the vaccine., “Said White House COVID-19 coordinator Jeff Zients. “So the US is looking at options to share AstraZeneca dosages with other countries as they are available.”
COVID-19 has killed more than 3 million people worldwide.
Approximately 10 million doses of the AstraZeneca vaccine have been produced, but have yet to pass a review by the FDA “to meet their expectations for product quality,” the patients said. This process can be completed in the next several weeks. About 50 million more doses are in various stages of production and may be available onboard for FDA sign-off in May and June.
The US has not yet decided where AstraZeneca’s dose will go, Zaders said. Neighboring Mexico and Canada have called on the Biden administration to share more doses, while dozens of other countries want to use vaccine supplies. The dose will be donated by the US government, which has contracted with the company for a total of 300 million doses – although the company has faced production issues.
AstraZeneca supplements in the US were produced at an Emergent Biosolution plant in Baltimore that has come under increased regulatory and public scrutiny after batching batches of the Jammu and Kashmir vaccine. The US pressed J&J to take over the plant and directed the closure of the AstraZeneca shot making facility in an effort to ensure the quality of the newly produced vaccines. AstraZeneca is still looking to identify a new US production facility for its future supplements.
AstraZeneca’s vaccine was initially expected to be the first to receive federal emergency authorization and the US government placed a substantial order for 150 million Americans before issues with clearance of clinical trials of the vaccine. The company’s 30,000-person US trial did not complete enrollment until January and it still has not filed for emergency use authorization with the FDA.
Leave a Reply